Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

被引：15

作者：

Loibl, Sibylle ^{[1
,2
]}

Furlanetto, Jenny ^{[1
]}

机构：

[1] GBG Forsch GmbH, Neu Isenburg, Germany

[2] Ctr Hematol & Oncol Bethanien, Frankfurt, Germany

来源：

BREAST | 2022年 / 62卷

关键词：

CDK4/6; inhibitors; Endocrine therapy; Hormone receptor positive breast cancer; Early setting; KINASE; 4/6; INHIBITOR; ENDOCRINE THERAPY; SAFETY ANALYSIS; DOUBLE-BLIND; PHASE-II; CYCLIN-D; PALBOCICLIB; COMBINATION; MULTICENTER; ANASTROZOLE;

D O I：

10.1016/j.breast.2021.12.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer. All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site of metastasis, CDK4/6 inhibitor used and associated endocrine therapy. A benefit in overall survival has also been demonstrated. In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility. Studies conducted in the neoadjuvant setting might help to explain the discordant results.(C) 2022 The Authors. Published by Elsevier Ltd.

引用

页码：S70 / S79

页数：10

共 76 条

[1]

[Anonymous], 2014, New J Sci

[2] The history and future of targeting cyclin-dependent kinases in cancer therapy [J].

Asghar, Uzma ;

Witkiewicz, Agnieszka K. ;

Turner, Nicholas C. ;

Knudsen, Erik S. .

NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (02) :130-146

[3] Efficacy of everolimus in patientswith HRD/HER2-high risk early stage breast cancer [J].

Bachelot, T. ;

Dalenc, F. ;

Chabaud, S. ;

Cottu, P. ;

Allouache, D. ;

Brain, E. ;

Jacquin, J-P. ;

Grenier, J. ;

Bouvet, L. Venat ;

Brunt, M. ;

Campone, M. ;

Del Piano, F. ;

Debled, M. ;

Bessard, A-C. Hardy ;

Giacchetti, S. ;

Bliss, J. ;

Canon, J-L. ;

Lemonnier, J. ;

Cameron, D. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2021, 32 (04) :574-575

[4]

Beck JT, 2019, CANCER RES, V79

[5] Cellular mechanisms of tumour suppression by the retinoblastoma gene [J].

Burkhart, Deborah L. ;

Sage, Julien .

NATURE REVIEWS CANCER, 2008, 8 (09) :671-682

[6] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer [J].

Burstein, Harold J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26) :2557-2570

[7] Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Cardoso, F. ;

Kyriakides, S. ;

Ohno, S. ;

Penault-Llorca, F. ;

Poortmans, P. ;

Rubio, I. T. ;

Zackrisson, S. ;

Senkus, E. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1194-1220

[8] Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance [J].

Chen, Ping ;

Lee, Nathan V. ;

Hu, Wenyue ;

Xu, Meirong ;

Ferre, Rose Ann ;

Lam, Hieu ;

Bergqvist, Simon ;

Solowiej, James ;

Diehl, Wade ;

He, You-Ai ;

Yu, Xiu ;

Nagata, Asako ;

VanArsdale, Todd ;

Murray, Brion W. .

MOLECULAR CANCER THERAPEUTICS, 2016, 15 (10) :2273-2281

[9] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[10] Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer [J].

Cottu, P. ;

D'Hondt, V. ;

Dureau, S. ;

Lerebours, F. ;

Desmoulins, I. ;

Heudel, P-E ;

Duhoux, F. P. ;

Levy, C. ;

Mouret-Reynier, M-A ;

Dalenc, F. ;

Frenel, J-S ;

Jouannaud, C. ;

Venat-Bouvet, L. ;

Nguyen, S. ;

Ferrero, J-M ;

Canon, J-L ;

Grenier, J. ;

Callens, C. ;

Gentien, D. ;

Lemonnier, J. ;

Vincent-Salomon, A. ;

Delaloge, S. .

ANNALS OF ONCOLOGY, 2018, 29 (12) :2334-2340

← 1 2 3 4 5 6 7 8 →